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Aspirin-induced asthma (AIA) and aspirin-induced urticaria/
angioedema (AIU) are two major aspirin-related allergies. We
summarize recent findings related to their molecular genetic
mechanisms in order to identify genetic susceptibility markers
for differentiating AIU and AIA. The overproduction of
cysteinyl leukotriene has been suggested as a mechanism in
both AIU and AIA. Increased expression of CYSLTR1 with
CYLSTR1 and CYSLTR2 polymorphisms are new findings in
AIA, while the ALOX5 promoter polymorphism has been
noted in AIU. An HLA study suggested that DPB1*0301 is a
strong genetic marker for AIA, and that HLA DRB1*1302 and
DQB1*0609 are markers for AIU susceptibility. Several
single nucleotide polymorphisms (SNPs) in the promoters of
EP2, TBX21, COX-2, Fc RI ε β, and TBXA2R were associated
with AIA, while an Fc RI ε α promoter polymorphism was
associated with AIU. The functional studies of the key genes
involved in AIA and AIU are summarized. The identification
and functional study of genetic markers for AIA and AIU
susceptibility would further elucidate the pathogenic mecha-
nisms and facilitate the development of early diagnostic
markers to establish therapeutic targets.
Key Words: Aspirin-induced asthma, aspirin-induced urti-
caria/angioedema, gene polymorphism, leukotrienes
INTRODUCTION
Aspirin (acetyl salicylic acid) ingestion induces
several allergic diseases, including aspirin-into-
lerant asthma (AIA), aspirin-induced acute or
chronic urticaria/angioedema (AIAU or AICU),
anaphylaxis, and rarely, hypersensitivity pneu-
monitis.
1,2 Of these conditions, AIA and AIU are
the most prevalent in Korea. Although the patho-
genic mechanism of AIA is not completely under-
stood, the chronic overproduction of cysteinyl
leukotrienes (Cys-LTs) derived from cyclooxy-
genase (COX) inhibition is a consistent finding.
3-6
In contrast to AIA, information on the pathogenic
mechanism of AIU is limited. Recent reports,
however, have suggested that Cys-LT overpro-
duction is one pathogenic mechanism, which is
also associated with AIU.
7-9 To explore the mole-
cular genetic mechanisms of AIA and AIU, we
performed several case-control studies to identify
gene markers for differentiating AIA and AIU,
focusing on HLA alleles and leukotriene-related
genes.
CLINICAL CHARACTERISTICS OF AIA AND
AIU
AIA is characterized by a typical sequence of
symptoms, including intense eosinophilic inflam-
mation of the upper and lower airways. It is
more commonly found in non-atopic, middle-
aged females and is strongly associated with
chronic rhinosinusitis and nasal polyposis.
10
Typically, the asthmatic symptoms can be clas-
sified as moderate to severe, and long-term
maintenance medications, including leukotriene-
receptor antagonists, are required to control the
asthma symptoms.
Aspirin ingestion can induce acute and chronic
urticaria. Chronic urticaria is defined as suffering
from daily urticaria symptoms for more than 6
weeks.
7 AIU can be confirmed by the oral aspirin
challenge test.
11,12 Based on these test results,
chronic urticaria patients are classified into two
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groups: those with chronic urticaria associated
with aspirin sensitivity (AICU) and those with
negative responses (chronic idiopathic urticaria,
CIU). In our previous study,
13 AICU patients
(compared to CIU patients) were found to be
younger and showed higher rates of atopy and
serum total IgE. No significant differences were
noted in the prevalence of thyroid autoanti-
bodies, antinuclear antibody, or other clinical
parameters.
A GENETIC APPROACH TO AIA
The HLA allele
The association between HLA-DPB1*0301 and
AIA was first reported in a Polish population,
14
and the results were replicated in a Korean
population.
15 The frequency of DPB1*0301 was
significantly higher in AIA patients compared to
normal and asthmatic controls, suggesting that
immune system recognition of an unknown anti-
gen is part of the pathogenesis of AIA.
14 In the
Korean population,
15 the patients with DPB1*0301
tended to have lower FEV1 levels, be female, and
have a higher prevalence of rhinosinusitis and
nasal polyps than those without it. These are the
typical clinical symptoms of AIA. Furthermore,
the presence of HLA-DPB1*0301 was significantly
associated with a higher leukotriene receptor an-
tagonist dose requirement in the long-term man-
agement of AIA patients.
16 We postulate that
HLA-DPB1*0301 is a strong genetic marker for
identifying the AIA phenotype.
Leukotriene-related genes and CYSLTR1
It has been suggested that the activity of the
leukotriene C4 synthase gene (LTC4S), a key en-
zyme in Cys-LT synthesis, is genetically regu-
lated in the pathogenesis of AIA. Two promoter
polymorphisms (-1072G > A and -444A > C) have
been identified, and LTC4S-444A > C was re-
ported to be positively associated with the AIA
phenotype in a Polish population.
17,18 The patients
with the C allele had a greater risk of developing
AIA. The adenosine to cytosine conversion of
this promoter polymorphism created an additio-
nal responsive element for histone H4 transcrip-
tion factor-2, increasing the transcription rate of
the gene both in vitro and in vivo. Patients car-
rying the LTC4S-444A homozygote had a greater
increase in urinary LTE4 after an aspirin chal-
lenge.
19 The association of this promoter poly-
morphism with the phenotype of AIA patients,
however, has not been replicated in other popu-
lations, including Japanese, American, and Korean
populations.
19-21
Some reports have suggested the possible
involvement of the 5-lipoxygenase gene (ALOX5)
in AIA. The Drazen group first identified the
promoter polymorphism of the ALOX5 gene,
which consisted of a variable number of tandem
repeats of GC-rich motifs associated with the
binding of Sp1 transcription factors.
22 Subjects
with the wild- type genotype (five repeats) had a
significantly higher capacity to produce Cys-LTs
compared to those with a mutant genotype (3, 4,
or 6 repeats). Furthermore, a significant associa-
tion between the ALOX5 promoter polymor-
phism and the severity of airway hyperrespon-
siveness was detected in the Korean population.
23
AIA patients carrying a mutant allele (n 5
repeats) showed increased airway hyperre-
sponsiveness compared to AIA patients with the
wild-type genotype. When we screened ten SNPs
for key enzymes involved in arachidonate meta-
bolism in a Korean population, 5-lipoxygenase
(ALOX5, -1708G > A, 21C > T, 270G > A, 1728G
> A), ALOX5-activating protein (ALOX5AP,
218A > G), cyclooxygenase 2 (COX-2, -162C > G,
10T > G, 228G > A), leukotriene C4 synthase
(LTC4S, -444A > C), and cysteinyl leukotriene
receptor 1 (CYSLTR1, 927T > C), the lack of an
association was noted between the ALOX5AP,
COX-2, and CYSLTR1 gene polymorphisms and
the AIA phenotype.
21 The possible involvement
of ALOX5-ht1 [G-C-G-A] of the ALOX5 gene
(-1708G > A, 21C > T, 270G > A, 1728G > A) in
AIA development, however, was suggested be-
cause the frequency of the [G-C-G-A] haplotype
of ALOX5 in the AIA group was significantly
higher than its frequency in the ATA group.
21
Cys-LTs exert their biological actions by
binding to two types of receptors: CYSLTR1 and
CYSLTR2. We have found genetic associations
between these two genes and AIA.
24,25 ThreeGenetic Markers for Differentiating Aspirin-Hypersensitivity
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SNPs (-634C > T, -475A > C, -336A > G) in the
5'-upstream region of CYSLTR1
24 were signifi-
cantly associated with the AIA phenotype, espe-
cially in males. Male AIA patients had higher
frequencies of the minor alleles, while no dif-
ferences were noted in females. Furthermore,
these promoter polymorphisms were associated
with increased promoter activity. A functional
study using two cell lines, human T lymphocytes
(Jurkat) and lung epithelial cells (A549), showed
enhanced promoter activity with the ht2 [T-C-G]
construct compared to the ht1 [C-A-A] construct,
suggesting that this polymorphism modulates
CYSLTR1 expression to increase AIA suscepti-
bility. Four SNPs of the CYSLTR2 polymorphism,
c.-819T > G, c.2078C >T, c.2534A > G, and c.2545
+297A > G, were found in a Korean population
25
and the frequencies of the rare alleles c.-819T >G,
c.2078C > T, and c.2534A > G were higher in those
with AIA than in those with ATA. Patients with
the rare alleles c.-819T > G, c.2078C > T, or
c.2534A> G exhibited a greater percentage drop
in FEV1 after aspirin provocation than those with
the common allele. These results suggest that
CYSLTR1 and ALOX5, but not LTC4S, can be
genetic markers for AIA susceptibility in the
Korean population.
COX, PGE2, and TBXA2R polymorphism
In a case-controlled study of 63 candidate genes
in a Japanese population,
26 a functional SNP of the
PGE2 receptor subtype 2 gene (EP2) was found to
be associated with the risk of AIA. This SNP may
act by reducing the PGE2 braking mechanism of
inflammation. Although a novel promoter poly-
morphism (-765G > C) of COX-2 was not asso-
ciated with AIA, the CC homozygote of this pro-
moter polymorphism was associated with in-
creased PGE2 production by creating an E2F tran-
scription factor binding motif.
27 Further studies
are needed to clarify the role of COX-2 and PG
imbalance in the pathogenic mechanisms of AIA
in a Korean population.
TBXA2R is a receptor for a potent bronchocon-
strictor, thromboxane A2 (TBXA2), and a TBXA2R
+ 795T > C polymorphism could augment the
bronchoconstrictive response to inhaled aspirin,
possibly contributing to AIA development in the
Korean population.
28 The effect of increased
TBXA2 production in the pathogenesis of AIA
could be explained by the fact that oral aspirin
administration uncouples the TBXA2-dependent
negative feedback mechanisms, which may, in
turn, increase the production of Cys-LTs.
29 The
TBXA2-dependent regulation of LTC4S activity
may be an important pathophysiological mecha-
nism in AIA.
Other candidate genes related to the AIA pheno-
type
We investigated two polymorphisms of Fc R1 ε β
(-109T > C and E237G) in a Korean population and
found no significant association between the
genotype distributions of these polymorphisms
and the phenotype of AIA.
30 However, a signifi-
cant association between the -109T > C polymor-
phism and IgE specific to staphylococcal entero-
toxin B (SEB) was found. The number of subjects
with both homozygous alleles of Fc R1 -109T ε β and
IgE specific to SEB was significantly greater in the
AIA group. Furthermore, luciferase reporter as-
says showed that the Fc R1 -109T ε β allele had
higher promoter activity in both the RBL-2H3 and
A549 cell lines, suggesting that the Fc R1 -109T ε β >
C polymorphism increases the expression of Fc R1 ε
β in mast cells. This may lead to the enhanced
release of proinflammatory mediators in the asth-
matic airway, and thereby contributing to in-
creased AIA susceptibility.
TBX21 encodes T-bet, a T-box transcription fac-
tor expressed in T cells, which influences naive T
lymphocyte development and has been impli-
cated in asthma pathogenesis.
31 The -1993T T >C
SNP in the TBX21 promoter was found to be
associated with an increased risk for AIA in a
Japanese population by increasing transcriptional
activity.
32 This genetic variation can cause inap-
propriate Th1 responses in the airway, leading to
severe airway inflammation in combination with
antigen-specific Th2 responses. That report con-
cluded that the Th1 response played a role in the
pathogenesis of AIA equal to that of the Th2
response.Seung-Hyun Kim and Hae-Sim Park
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A GENETIC APPROACH TO ASPIRIN-IN-
DUCED URTICARIA
HLA gene markers for AIU patients
We demonstrated an association between the
HLA genotype and AIU using a high-resolution
analysis technique and confirmed a strong posi-
tive association between the HLA-DRB1*1302 and
HLA-DQB1*0609 alleles in AIU patients.
33 The al-
lele frequencies of HLA-DRB1*1302 and HLA-
DQB1*0609 in AIU patients were significantly
higher than in AIA patients and normal controls
(NC). In this study, we suggested that HLA-
DRB1*1302-DQB1 *0609-DPB1*0201 is a strong
genetic determinant of the AIU phenotype. This is
the first study to demonstrate a positive associa-
tion between an HLA allele and the AIU pheno-
type. It suggests that among patients suffering
from aspirin- or NSAID-related allergies, subjects
carrying the HLA- DPB1*0301 allele may repre-
sent the AIU phenotype, while those carrying
HLA-DRB1* 1302 or HLA-DQB1*0609 may repre-
sent the AIU phenotype.
Cys-LT-related gene polymorphisms in AIU
patients
Although there is no clear evidence of the in-
volvement of Cys-LTs in AIU, it has been pro-
posed that Cys-LTs participate in the patho-
genesis of urticaria and angioedema, by a
mechanism similar to that in AIA. Mastalerz et
al. demonstrated the overproduction of Cys-LT
in association with the LTC4S polymorphism in
chronic urticaria patients with aspirin sensi-
tivity.
34 The frequency of subjects carrying the C
allele of LTC4S-444A > C was significantly higher
in chronic urticaria patients who tested positive
in the aspirin challenge test than those who
tested negative. No association, however, was
found between the LTC4S-444A > C polymor-
phism and the phenotype of NSAID-induced
isolated periorbital angioedema in Spanish
35 or
Korean populations.
36 We also investigated the
genetic polymorphisms of candidate genes en-
coding enzymes which are involved in leuko-
triene synthesis in a Korean population.
36 Of the
eight SNPs in the four leukotriene-related genes,
ALOX5, ALOX5AP (5-lipoxygenase activating
protein), and PTGS2 (cyclooxygenase 2), as well
as the polymorphism of ALOX5 at position -1708
G > A, showed a significant difference in geno-
typic frequency between AIU and AIA. The
frequency of the ALOX5-1708A allele in the AIU
group was significantly lower than that in the
AIA group. No significant differences were noted
in the other SNPs, suggesting that ALOX5 makes
different contributions in AIU and AIA, and in
AIU and NC.
Table 1. Summary of the Genetic Studies of AIA in a Korean Cohort
Gene Loci SNPs Phenotype Risk Number of patients
ALOX5 10q11 ht1[GCGA] AIA Higher 93
10q11 (GGGCGG)4,6 AHR Higher 107
Fc RI ε β 11q13 -109T > C IgE to SEB Lower 107
TBXA2R 19p13.3 795T > C FEV1 fall after L-aspirin BPT* Higher 93
CYSLTR1 Xq24 -634C > T AIA Higher 105
CYSLTR2 13q14.2-21.1 c.-819T > G AIA FEV1 fall after L-aspirin BPT Higher 115
13q14.2-21.1 c.2078C > T
13q14.2-21.1 c.2534A > G
HLA 6 DPB1*0301 AIA Higher 76
AIA, aspirin-intolerant asthma; AHR, airway hyperresponsiveness; BPT, bronchial provocation test; SEB, staphylococcal enterotoxin B;
FEV1, forced expiratory volume in one second.Genetic Markers for Differentiating Aspirin-Hypersensitivity
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Histamine-related genes in chronic urticaria with
aspirin sensitivity
Considering the pathogenic mechanisms of
AIU, we postulate that the polymorphisms of
candidate genes involved in histamine release
and metabolism and their receptors (H1 and H2
receptors) are associated with the AIU pheno-
type. First, we analyzed 11 known SNPs of the
high- affinity IgE receptor I (Fc RI ), histamine ε β
N-methyl transferase (HNMT), histamine recep-
tor type 1 (HRH1), histamine receptor type 2
(HRH2), and their haplotypes in AIU patients,
and compared them to other drug allergy patients
and normal controls. No significant differences
were observed in allele or genotype frequencies,
and the haplotype frequencies of all SNPs of Fcε
RI , HNMT, HRH1, and HRH2 were similar in β
the three groups.
37 This finding suggests that
polymorphisms of Fc RI ε β and the three hista-
mine-related genes do not contribute to the
development of the AIU phenotype in the
Korean population. We also investigated two
genetic polymorphisms (-344C > T, -95 T > C) of
the Fc RI ε α gene in patients with aspirin-induced
chronic urticaria (AICU), and compared them to
patients with aspirin-tolerant chronic urticaria
(ATCU) and NC.
38 Of the two genetic polymor-
phisms of Fc RI ε α, AICU patients had a signifi-
cantly higher frequency of the genotype con-
taining the -344T allele than the ATCU and NC
groups. No significant differences were noted in
the genotype or allele frequencies of the -95T > C
polymorphism among the three groups. In
addition, the genetic variants of Fc RI -344C ε α > T
appeared to increase promoter activity in both
the A549 and RBL-2H3 cell lines. These findings
suggest that the Fc R1 -335C ε α > T polymorphism
contributes to the development of AICU by
increasing the promoter activity. Further inves-
tigation is needed to elucidate whether this
genetic variant can increase histamine releasabi-
lity or augment the signaling from mast cells,
which leads to the release of proinflammatory
mediators. Table 2 summarizes the gene lists
representing the phenotype of AIU.
DIAGNOSIS AND MANAGEMENT
The diagnosis of aspirin sensitivity can be made
with certainty using challenge tests involving
increasing doses of aspirin. There are four types
of challenge tests based on the route of aspirin
administration: oral, bronchial, nasal, and rarely,
intravenous tests.
11,12 Both the oral and bronchial
tests have similar specificities, although the oral
test has somewhat greater sensitivity. Because the
oral aspirin challenges can induce severe reactions
and take several days to complete, the lysine-as-
pirin bronchial challenge test is widely used in
European and Asian countries.
12 As an in vitro
test, the measurement of 15-HETE induced from
peripheral blood by aspirin has been suggested as
a specific test for aspirin-sensitive patient identifi-
cation (ASPI test).
39
When aspirin sensitivity is confirmed in both
AIA and AIU patients, the complete avoidance of
aspirin/NSAIDs is crucial to prevent life-threa-
tening, adverse reactions. Moreover, the avoid-
ance of salicylate-containing foods is recom-
mended. The basic principle of pharmacotherapy
for AIA is step-wise treatment based on anti-
inflammatory medications. A leukotriene receptor
antagonist (LTRA) is the first line agent for
AIA,
40-42 and LTRA has a beneficial effect in rhi-
nitis/nasal polyposis. Aspirin desensitization
may reduce the inflammatory mucosal symptoms
Table 2. Summary of the Genetic Studies of AIU in a Korean Cohort
Gene Loci SNPs Phenotype Risk Number of patients
HLA 6 DRB1*1302 AIU Higher 188 AIU
6 DQB1*0609 AIU Higher 188 AIU
ALOX5 10q11 -1708G > A AIU Higher 101 AIU
Fc RI ε α 1q23 -344C > T AICU Higher 95 AICUSeung-Hyun Kim and Hae-Sim Park
Yonsei Med J Vol. 47, No. 1, 2006
of the upper and lower airways. Antihistamines
are the first-line pharmacotheraputic treatment




Further information on the genetic polymor-
phisms of these candidate genes with supporting
functional studies will make it possible to eluci-
date the molecular mechanisms of two major
aspirin-related conditions, AIA and AIU, and
should lead to the identification of genetic suscep-
tibility markers for differentiating AIA and AIU.
This will lead to the development of new diag-
nostic markers and provide additional therapeutic
targets based on genetic information.
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